Los Tres Paso Trial: Step One - Neoadjuvant Palbociclib Monotherapy, Step Two - Concurrent Chemoradiation Therapy, and Step Three - Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
Latest Information Update: 04 Jul 2023
At a glance
- Drugs Palbociclib (Primary) ; Cetuximab; Cisplatin
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms Los Tres Paso
- 06 Jun 2023 Results assessing Correlation of CDKN2A genomic alterations with tumor response to palbociclib given before chemoradiation therapy to patients with human papillomavirus negative, locally advanced head and neck squamous cell carcinoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 21 Dec 2021 Planned End Date changed from 31 Jan 2028 to 6 Apr 2027.
- 21 Dec 2021 Planned primary completion date changed from 31 Oct 2022 to 15 Feb 2022.